Impact Biomedical’s ownership in the suite is estimated to be at $1.32 billion.
SINGAPORE (June 1): Singapore eDevelopment (SeD) announced on Monday that its wholly-owned subsidiary Impact Biomedical’s suite of antiviral and medical technologies, which is co-owned by its scientific research partner, Global Research and Discovery Group Sciences (GRDG Sciences), is valued at $1.97 billion.
The valuation was conducted by independent experts who specialise in assessing the potential deal value of medical intellectual property.
